Initiate Phase 3 pivotal program for DURAVYU in diabetic macular edema
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 5 Feb 2025
- Due
- 31 Dec 2025
- Delivered
- 14 Oct 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Phase 3 non-inferiority pivotal program initiation anticipated by the end of 2025”
What we found
Evidence strength B What the grades mean
EyePoint announced pivotal Phase 3 DME program (COMO and CAPRI) initiation on October 14, 2025, before the year-end 2025 deadline, though first dosing occurred in Q1 2026.
-
B EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU in Diabetic Macular Edema Company press release announcing Phase 3 DME program initiation with dosing anticipated Q1 2026
-
B EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU for Treatment of Diabetic Macular Edema (DME) Confirms both Phase 3 DME trials fully enrolled and underway
-
D EyePoint Begins Phase 3 Trials of Duravyu for DME Reports first patients dosed in COMO and CAPRI Phase 3 DME trials
Checked 14 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Initiate
- Language
- Expected (“expects”, “plans”)
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesGemini (Google) re-read the evidence blind and read it as “Not met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and reads it as “no_evidence”.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you EyePoint Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-EYPT-000248 · Corrections policy